What is Capture-SELEX? Unlike traditional SELEX where the target is immobilized, Capture-SELEX immobilizes the initial DNA library itself via a short complementary "capture" sequence. The key target molecule is free in solution. Binding occurs when an aptamer candidate in the library binds to the target, causing a structural change that releases it from the immobilization surface. This approach offers distinct advantages: Ideal for small molecules and proteins: Especially targets that are difficult to immobilize without affecting their structure. Minimizes non-specific binding: Selection pressure is purely for target-induced structure formation/release. Enriches for structure-switching aptamers: Resulting aptamers often undergo conformational change upon binding, making them excellent for biosensor development. Typical Capture-SELEX Screening Service Workflow A professional service provider will manage this complex, iterative process from start to finish. Here’s what you can expect: Phase 1: Project Design & Library Preparation Consultation & Target Specification: Defining target properties, desired affinity (Kd), specificity (against which counter-targets), and buffer conditions. Customized Library Design: Designing a single-stranded DNA library (10^14 - 10^15 unique sequences) with: A central random region (e.g., 30-50 nucleotides). Fixed primer regions for PCR amplification. A capture sequence region complementary to an immobilized oligonucleotide. Immobilization Matrix Preparation: Coupling the complementary "capture" oligonucleotides to a solid support (e.g., magnetic beads, chromatography resin). Phase 2: The Iterative Selection (SELEX) Cycles…
Small molecules are some of the most valuable—and most difficult—targets in molecular recognition. They include metabolites, drugs, toxins, cofactors, and signaling compounds that often weigh only a few hundred Daltons. Developing expertise in aptamers to small molecules means mastering a set of selection and validation strategies that differ substantially from protein-target aptamer work, because small molecules offer fewer contact points, weaker “handles” for separation, and more ways to generate false positives. This article explains how small-molecule aptamers are discovered, why selection is uniquely challenging, how advanced SELEX variants improve success rates, and what “good” looks like when you engineer an aptamer into a sensor, assay, or therapeutic concept. 1) What makes small-molecule aptamers special? Aptamers are single-stranded DNA or RNA sequences that fold into 3D shapes able to bind a target through non-covalent interactions—hydrogen bonding, π–π stacking, electrostatics, and shape complementarity. For proteins, large surfaces provide many contacts, so binding can be robust even when the selection workflow is imperfect. Small molecules are different: Tiny binding interface: fewer interaction opportunities means affinity can be harder to evolve and easier to mis-measure. Separation is tricky: in classic SELEX you often immobilize the target; immobilization can change the target’s presentation…
